Adial encouraged by U.S. Senate support for extended AUD trial endpoints

Adial Pharmaceuticals (ADIL) “applauded” recent U.S. Senate legislative support for expanding clinical trial endpoints beyond abstinence in substance use disorder treatments, including Alcohol Use Disorder, AUD. The U.S. Senate’s move to encourage the FDA to develop new endpoints for AUD to enhance the regulatory pathway for new pharmaceutical candidates strongly reinforces Adial’s clinical development strategy for AD04, its lead investigational drug, a serotonin-3 receptor antagonist, being developed for the treatment of AUD in individuals with heavy drinking and select genotypes.